Topic: Brilinta
Patients hoping for a new alternative to the blockbuster blood thinner Plavix will have to wait a bit longer for a verdict on a promising candidate. Although a panel of advisors to the FDA had voted 7-1 for Brilinta's approval in July, ...
Federal regulators need an additional three months to complete a review of an experimental blood thinner made by AstraZeneca, the company said Wednesday.. In July, FDA advisory committee members voted 7 to 1 to recommend the approval of Brilinta in patients with ...
Following a federal health panel's endorsement of the new blood thinner Brilinta Wednesday, cardiologists say the drug could be a welcome addition to treatments for heart patients.. The panel's nod was partly based on the results of a clinical trial, called PLATO, ...
An FDA advisory committee's strong vote in favor of AstraZeneca's (AZN) blood-thinner Brilinta was tempered by long-held concerns over the failure of the drug's pivotal trial to show a survival benefit in the US population when compared to Plavix (Event - Brilinta ...
ADELPHI, Maryland (Reuters) - U.S. advisers backed a potential blockbuster blood thinner from AstraZeneca on Wednesday, a victory for a company seeking new drugs to offset expiring patents on some of its best-selling medicines.Members of a Food and Drug Administration panel voted ...
3/16/2010 Print E-mail In a trial comparing two anti-clotting drugs, patients given Brilinta before cardiac bypass surgery were less likely to die than those given Plavix, researchers found.. "Ticagrelor (Brilinta) in this setting, with acute coronary syndrome patients with the potential need ...
In a trial comparing two anti-clotting drugs, patients given Brilinta before cardiac bypass surgery were less likely to die than those given Plavix, researchers found.. "Ticagrelor (Brilinta) in this setting, with acute coronary syndrome patients with the potential need for bypass surgery, ...
1/14/2010 Print E-mail A new clot-busting drug, Brilinta, may soon take the place of Plavix in treating patients with acute coronary syndrome, which includes angina and heart attack.. In a new trial, the upstart drug, ticagrelor (Brilinta) reduced the risk of second ...
A new anticlotting drug works better than Plavix, one of the most prescribed and most profitable drugs in the world, a huge clinical trial finds.. That approval seems likely, given the results of a new clinical trial that compared Plavix to Brilinta ...
AstraZeneca today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The ...
